Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).

Authors: Alicia K. Morgans, Maelys Touya, Nader N. El-Chaar, Dina Elsouda, Krishnan Ramaswamy, Kelechi L. Adejumo, Danielle Gentile, Bruce A. Feinberg, Parisa Asgarisabet, Prathamesh Pathak, Stephen J. Freedland

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.354

Source: Full article

---

Abstract

354